Detalles de la búsqueda
1.
Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer.
N Engl J Med
; 388(18): 1645-1656, 2023 May 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37133584
2.
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
N Engl J Med
; 384(16): 1529-1541, 2021 04 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-33882206
3.
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
N Engl J Med
; 384(25): 2394-2405, 2021 06 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-34081848
4.
Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer.
J Natl Compr Canc Netw
; 21(1): 33-41.e16, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36634607
5.
DECRESCENDO: de-escalating chemotherapy in HER2-positive, estrogen receptor-negative, node-negative early breast cancer.
Future Oncol
; 19(24): 1655-1667, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37609714
6.
Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy-a sub-analysis of the ALTTO study.
Br J Cancer
; 127(10): 1799-1807, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36050448
7.
ROSALINE: a phase II, neoadjuvant study targeting ROS1 in combination with endocrine therapy in invasive lobular carcinoma of the breast.
Future Oncol
; 18(22): 2383-2392, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35695563
8.
70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.
Lancet Oncol
; 22(4): 476-488, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33721561
9.
STAT3 activation in HER2-positive breast cancers: Analysis of data from a large prospective trial.
Int J Cancer
; 148(6): 1529-1535, 2021 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33152119
10.
Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer.
Br J Cancer
; 125(1): 38-47, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33828257
11.
Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D).
Breast Cancer Res Treat
; 185(1): 107-116, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-32951084
12.
Neo-CheckRay: radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trial.
BMC Cancer
; 21(1): 899, 2021 Aug 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34362344
13.
Body Mass Index and Weight Change in Patients With HER2-Positive Early Breast Cancer: Exploratory Analysis of the ALTTO BIG 2-06 Trial.
J Natl Compr Canc Netw
; 19(2): 181-189, 2021 01 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33401235
14.
International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium.
Lancet Oncol
; 21(2): e83-e96, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32007209
15.
Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial.
Breast Cancer Res
; 22(1): 115, 2020 10 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-33109233
16.
Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial.
Br J Cancer
; 122(10): 1453-1460, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32203207
17.
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
N Engl J Med
; 377(2): 122-131, 2017 Jul 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-28581356
18.
Computed tomography-based analyses of baseline body composition parameters and changes in breast cancer patients under treatment with CDK 4/6 inhibitors.
Breast Cancer Res Treat
; 181(1): 199-209, 2020 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-32246377
19.
Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy.
Int J Mol Sci
; 21(4)2020 Feb 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-32085669
20.
Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Oncol
; 20(9): 1226-1238, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31402321